Lyra Therapeutics LYRA Balance Sheet (2019-2025)

LYRA
$0.19 +0.00 (+0.00%)
At close: Sep 8, 2026 · 4:00 PM EDT
Reported Financials

Lyra Therapeutics Quarterly Balance Sheet

Periods 28 quarters
Latest Dec 2025

Lyra Therapeutics reported total assets of $36.11M and total liabilities of $46.83M for the quarter ended Dec 2025, down 45.6% year over year. This balance sheet covers 28 quarters of results from Mar 2019 through Dec 2025, standardized by Business Quant from the company’s SEC filings.

Balance Sheet Mar2019 Jun2019 Sep2019 Dec2019 Mar2020 Jun2020 Sep2020 Dec2020 Mar2021 Jun2021 Sep2021 Dec2021 Mar2022 Jun2022 Sep2022 Dec2022 Mar2023 Jun2023 Sep2023 Dec2023 Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025 Dec2025
Accumulated Depreciation
2.95M3.25M3.60M3.88M4.16M4.45M4.72M4.17M1.92M2.20M2.24M4.13M4.26M4.34M4.45M4.55M
Assets
Current Assets
Cash & EquivalentsCash & Equiv.
66.11M69.05M58.13M46.08M34.08M122.09M110.98M33.94M23.41M55.75M26.24M23.75M17.79M33.90M25.79M40.58M31.73M29.80M22.10M15.90M
Receivables - OtherOther Receivables
Prepaid Assets
1.25M1.03M2.75M2.17M1.80M1.38M2.34M2.94M2.09M1.80M2.37M2.07M2.33M1.94M2.82M2.45M2.17M1.28M0.96M0.38M
Current Assets
67.35M70.07M60.89M47.92M40.55M122.38M112.23M100.83M84.80M118.25M104.92M104.82M89.44M69.44M54.44M43.02M33.91M31.06M23.02M16.27M
Non-Current Assets
Property, Plant & Equipment (Net)
3.17M3.85M4.71M4.50M4.28M4.01M3.75M2.24M2.00M0.56M0.73M2.04M3.78M1.67M1.61M1.40M1.28M1.16M1.12M1.05M
Other Non-Current Assets
0.33M0.33M0.33M0.76M1.08M1.70M1.78M3.30M3.85M4.35M7.46M1.39M1.99M1.99M1.99M1.99M1.99M1.99M1.99M1.99M
Non-Current Assets
5.57M6.26M6.88M6.95M6.79M7.65M7.23M9.14M9.07M7.42M15.65M37.78M52.08M25.15M24.31M23.32M22.41M21.51M20.69M19.84M
Assets
72.92M76.33M67.76M54.87M47.34M130.03M119.46M109.97M93.87M125.67M120.58M142.60M141.53M94.58M78.76M66.35M56.32M52.57M43.71M36.11M
Liabilities
Current Liabilities
Accounts Payables
1.17M1.90M2.91M3.12M2.41M1.67M2.90M2.62M3.95M4.19M5.05M3.13M2.84M4.97M2.29M1.18M0.72M0.68M0.63M0.66M
Payables
1.17M1.90M2.91M3.12M2.41M1.67M2.90M2.62M3.95M4.19M5.05M3.13M2.84M4.97M2.29M1.18M0.72M0.68M0.63M0.66M
Accumulated Expenses
1.99M2.98M3.97M4.26M4.24M5.46M7.32M9.03M6.79M6.74M11.05M9.37M10.06M6.09M4.86M4.35M4.04M3.49M3.06M3.27M
Other Accumulated Expenses
0.06M0.07M0.13M0.63M0.04M0.12M0.30M0.66M1.23M0.47M0.52M
Current Leases
1.01M1.03M1.05M1.07M1.10M0.93M0.65M1.55M1.90M1.69M1.40M5.43M4.50M4.27M4.00M4.12M4.24M4.55M4.68M4.82M
Current Deferred Revenue
12.00M9.84M11.71M16.25M15.72M15.36M15.35M14.94M14.48M13.94M13.79M13.26M12.66M12.47M12.26M12.08M11.89M11.87M11.86M
Total Current Liabilities
4.17M5.90M17.77M18.25M21.96M10.61M13.61M14.47M14.15M14.11M19.23M19.60M18.72M19.28M14.95M12.63M11.47M11.16M9.48M9.52M
Non-Current Liabilities
Non-Current Deffered Revenue
2.15M1.93M2.02M13.18M12.63M14.08M13.43M12.99M12.21M12.14M11.94M11.85M11.86M11.86M11.86M11.86M11.86M11.86M
Preferred Stock Liabilities
Operating Leases
1.20M0.93M0.66M0.38M0.10M0.00M0.00M0.67M0.19M4.89M21.45M33.36M32.48M31.32M30.26M29.11M27.93M26.70M25.44M
Total Non-Current Liabilities
5.37M18.83M20.57M20.55M24.09M23.79M29.21M27.10M36.34M53.18M64.02M63.60M58.14M54.75M52.44M50.95M48.04M
Total Liabilities
5.37M18.83M20.57M20.55M24.09M23.79M26.24M29.21M27.78M27.10M36.34M53.18M64.02M63.60M58.14M54.75M52.44M50.95M48.04M46.83M
Shareholder's Equity
Common Equity
67.55M57.50M47.19M34.32M23.26M106.25M93.22M80.75M66.09M98.58M84.24M89.42M77.50M30.98M20.62M11.59M3.87M1.62M-4.33M-10.72M
Liabilities and Shareholders Equity
72.92M76.33M67.76M54.87M47.34M130.03M119.46M109.97M93.87M125.67M120.58M142.60M141.53M94.58M78.76M66.35M56.32M52.57M43.71M36.11M
Retained Earnings
-157.69M-168.72M-179.80M-193.40M-205.31M-219.70M-234.44M-248.68M-264.93M-280.55M-296.20M-311.36M-333.81M-381.94M-393.81M-404.79M-413.34M-420.80M-426.80M-433.71M
Treasury Shares